LOS ANGELES (AP) — A New Jersey pharmaceutical company has agreed to pay $280 million to settle a federal lawsuit alleging it committed fraud promoting two cancer drugs for unapproved purposes. The lawsuit filed in federal court by a former sales manager alleged the company submitted false claims to Medicare and health care programs in 28 U.S.